Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease...

Introduction Oxidative stress has been suggested to play a key role in pathogenesis of multiple sclerosis (MS), but clinical data on oxidative stress markers in MS patients and their influence on clinical and radiologic characteristics of the disease are inconsistent. The aim of this study is to assess the serum levels of malondialdehyde (MDA) as a measure of lipid peroxidation in MS patients and its relation to disease characteristics. Methods This case control study included 120 patients with clinically definite relapsing remitting multiple sclerosis (RRMS) compared to 120 age and sex -matched healthy controls. MDA levels were measured using thiobarbituric acid reactive substances (TBARS) assay. Results MDA levels are significantly higher in patients with MS than those in control (P<0.001) especially during relapse, MDA levels are higher in patients taking no disease modifying therapy (DMT) than those taking interferon (IFN-β). MDA levels significantly correlate with expanded disability status scale (EDSS) (P<0.001). Conclusions The results of this study can provide evidence about the incrimination of oxidative stress in MS pathogenesis and disease disability and support the use of antioxidants as a new target of treatment that focuses on neutralizing free radicals and increases antioxidant capacity.